Company: FTII
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001641172-25-011790
Chunk: 4

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Item 8
Chunk 4
---
 Account.

     F-6 

Note 1 – Description of Organization
and Business Operations, Going Concern and Basis of Presentation (Continued)

Business Combination

On September 16, 2024, the
Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Longevity Biomedical, Inc., a Delaware
corporation (“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of the Company
(“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative.

The Merger Agreement provides
that the parties thereto will enter into a business combination transaction (the “Longevity Business Combination” and together
with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among other things,
(i) Longevity will consummate Target Acquisitions (as defined therein) upon the terms and subject to conditions set forth therein and
pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation of the Target Acquisitions,
Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following
the Merger, Longevity will be a wholly-owned subsidiary of the Company. At the closing of the Transactions (the “Closing”),
the Company is expected to change its name to “Longevity Biomedical, Inc.” and the Company’s common stock is expected
to list on the NASDAQ Stock Market under the ticker symbol “LBIO.”

The consummation of the proposed
Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement.

In connection with the
execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered into a
Voting and Support Agreement (the “Longevity Support Agreement”) with the Company and Longevity, pursuant to which the Voting Stockholder has agreed
to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by
certain other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to
cause the approval of the Transactions on behalf of Longevity.

In connection with the
execution of the Merger Agreement, the Company, Longevity and the Sponsor have entered into a Voting